Folic acid appears to hold promise as a potential preventive and therapeutic agent in gastric precancerous lesions. Folic acid, as an essential cofactor in DNA synthesis and methylation, plays a crucial role in maintaining genomic stability and regulating gene expression. It promotes DNA repair processes and protects against DNA damage, thereby inhibiting the initiation and progression of precancerous lesions. Moreover, folic acid acts as an antioxidant, mitigating oxidative stress and reducing inflammation in the gastric mucosa, which are key factors in the development of these lesions. Preclinical studies consistently demonstrate its protective effects against lesion development and progression, while clinical studies provide preliminary evidence for its efficacy in lesion regression or risk reduction. However, further well-designed clinical trials are needed to establish a definitive causal relationship, optimize folic acid supplementation strategies, and determine the optimal dosage and duration for gastric precancerous lesion management.
Keywords: Folic Acid, Gastric Precancerous Lesion, DNA, Supplement